Table 1 Age, gender distribution of the 3 patient cohorts and the respective distribution of Aβ phases, Aβ-MTL phases, A-scores, Braak NFT-stage, CERAD neuritic plaque score, NIA-AA degree of AD pathology, diagnosis, PET-Aβ phase estimate, B-Aβ stage, B-Aβ plaque stage, Aβ load. Short description of the recruitment criteria of the cohorts and case selection criteria for this study
Cohort 1 | Cohort 2 | Cohort 3 | |
|---|---|---|---|
German cases | Leuven cases | [18F]flutemetamol phase 3 autopsy cases | |
Number of cases | 95 | 79 | 97 |
Age in years (mean/range) | 72,43 (35–98) | 67,43 (34–90) | 80,86 (59–95) |
male/female | 48/47 | 54/25 | 45/52 |
Aβ phase (mean/range) | 2,34 (0–5) | 1,8 (0–5) | 3,65 (0–5) |
AβMTL phase (mean/range) | 1,96 (0–4) | 1,47 (0–5) | 2,92 (0–4) |
A-score (mean/range) | 1,49 (0–3) | 1,18 (0–3) | 2,39 (0–3) |
Braak NFT-stage (mean/range) | 2,11 (0–6) | 2,27 (0–6) | 3,95 (0–6) |
CERAD neuritic plaque score (mean/range) | 0,53 (0–3) | 0,66 (0–3) | 1,86 (0–3) |
NIA-AA degree of AD pathology (mean/range) | 1,11 (0–3) | 0,97 (0–3) | 2,01 (0–3) |
Diagnosis (control/p-preAD/AD/AD+non-AD-D*/non-AD-D*) | 24/35/13/5/18 | 18/4/15/8/34 | 3/8/33/28/25 |
PET-Aβ phase estimate (mean/range) | n.a. | n.a. | 1,81 (0–3) |
Aβ load / % (mean/range) | 4,16 (0–23,34) | n.a. | 6,75 (0–17,63) |
B-Aβ stage (mean/range) | 1,42 (0–3) [n = 38] | n.a. | n.a. |
B-Aβ plaque stage (mean/range) | 1,74 (0–3) [n = 70] | n.a. | n.a. |
CAA severity grade (Vonsattel) | 1 (0–3) | 0,84 (0–3) | 1,51 (0–3) |
CAA stage of topographical distribution | 1,1 (0–3) | 0,72 (0–3) | 1,64 (0–3) |
CDR | 0,993 (0–3) [n = 88] | 1622 (0–3) [n = 74] | n.a. |
MMSE | n.a. | n.a. | 9,48 (0–30) [n = 65] |
Scan-death interval | n.a. | n.a. | 215 (0–846) days |
Recruitment strategy | Hospital-based autopsies | Memory clinic-based cohort | Terminally ill with life-expectancy of less than 3 years, ≥55 years of age, no pregnancy, no allergy against [18F]flutemetamol, physical status allows to undergo PET imaging |
Case selection criteria | Aβ phases, AβMTL phases and Aβ loads already determined in the context of previous studies | Aβ phases and AβMTL phases already determined for biobank purposes | [18F]flutemetamol amyloid PET images are available that allow the measurement of SUVRcort and SUVRcaud |